Product Information
PITAVASTATIN 2 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.9543 per EA under NDC 00378505677. Its NADAC has been published 142 times since Jan 17, 2024.
FDA first approved this application on Apr 4, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378505677
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PITAVASTATIN CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA206070FDA Approved
4/4/2019
TE Code
AB
On Market Since
11/2/2023
Pharmacological Classes
Price Statistics
The NADAC for PITAVASTATIN 2 MG TABLET has been published 142 times since Jan 17, 2024, and over the history we have for it it has declined 53.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9543 per EA |
|---|---|
| All-time high | $2.4472 (Apr 10, 2024) |
| All-time low | $0.9543 (Sep 23, 2026) |
| 52-week high | $1.4525 |
| 52-week low | $0.9543 |
| Median price | $1.4780 |
| Average price | $1.5223 |
| Largest weekly change | -32.5% (Nov 20, 2024) |
| Weeks tracked | 142 |
| Tracking since | Jan 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the pitavastatin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pitavastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PITAVASTATIN 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PITAVASTATIN 2 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.9543 per EA (NDC 00378505677), effective Sep 30, 2026.
How has the price of PITAVASTATIN 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for PITAVASTATIN 2 MG TABLET has declined 53.4%. It has been tracked across 142 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for PITAVASTATIN 2 MG TABLET?
Since Jan 17, 2024, the NADAC for PITAVASTATIN 2 MG TABLET has ranged from a low of $0.9543 (Sep 23, 2026) to a high of $2.4472 (Apr 10, 2024), with a median of $1.4780 per EA.
Are there cheaper alternatives to PITAVASTATIN 2 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PITAVASTATIN 2 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PITAVASTATIN 2 MG TABLET?
PITAVASTATIN 2 MG TABLET (NDC 00378505677) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.